Stock Events

Stock Events

Monopar Therapeutics 

$123.84
36
+$4.79+4.02% Wednesday 20:00
-$0.04-0.03%Wednesday 23:53After hours

Statistics

Day High
124.27
Day Low
117.71
52W High
124.82
52W Low
29.18
Volume
13,673
Avg. Volume
-
Mkt Cap
831.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1
-0.78
-0.57
-0.35
Expected EPS
-0.800333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-13.72MNet Income

Analyst Ratings

121.00Average Price Target
The highest estimate is 133.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MNPR. It's not an investment recommendation.
NVIDIA
8
NVDA
D-Wave Quantum
8
QBTS
Apple
7
AAPL
Microsoft
6
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a biopharmaceutical company that competes in developing treatments for life-threatening diseases, overlapping with Monopar's focus on severe and life-threatening diseases.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech firm focusing on novel therapies, including for cancer and other serious illnesses, directly competing with Monopar's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb operates in the oncology space, developing cancer treatments that could compete with Monopar's cancer-focused pipeline.
Merck
MRK
Mkt Cap335.14B
Merck is known for its strong oncology portfolio, including therapies for various cancers, which competes with Monopar's cancer treatment developments.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad range of therapeutic products, including in oncology, which competes with Monopar's focus areas.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a significant presence in oncology and other serious health conditions, competing with Monopar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals focuses on developing drugs for serious diseases, including cancer, making it a competitor to Monopar.
Novartis
NVS
Mkt Cap286.78B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, competing with Monopar's focus.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a significant oncology portfolio, directly competing with Monopar's cancer therapy developments.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for various diseases, including cancer, competing with Monopar's therapeutic focus.

About

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Show more...
CEO
Chandler D. Robinson
Employees
22
Country
United States
ISIN
US61023L2079
WKN
000A40JML

Listings

STU
DE
1IY0.STU
STU
DE
1IY.STU
MU
DE
1IY0.MU
F
DE
1IY0.F

0 Comments

Share your thoughts

FAQ

What is Monopar Therapeutics stock price today?▼
The current price of MNPR is $123.84 USD — it has increased by +4.02% in the past 24 hours. Watch Monopar Therapeutics stock price performance more closely on the chart.
What is Monopar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Monopar Therapeutics stocks are traded under the ticker MNPR.
Is Monopar Therapeutics stock price growing?▼
MNPR stock has risen by +12.16% compared to the previous week, the month change is a +16.94% rise, over the last year Monopar Therapeutics has showed a +275.27% increase.
What is Monopar Therapeutics market cap?▼
Today Monopar Therapeutics has the market capitalization of 831.24M
When is the next Monopar Therapeutics earnings date?▼
Monopar Therapeutics is going to release the next earnings report on November 06, 2026.
What were Monopar Therapeutics earnings last quarter?▼
MNPR earnings for the last quarter are -0.62 USD per share, whereas the estimation was -0.64 USD resulting in a +3.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Monopar Therapeutics revenue for the last year?▼
Monopar Therapeutics revenue for the last year amounts to 0 USD.
What is Monopar Therapeutics net income for the last year?▼
MNPR net income for the last year is -13.72M USD.
How many employees does Monopar Therapeutics have?▼
As of August 20, 2026, the company has 22 employees.
In which sector is Monopar Therapeutics located?▼
Monopar Therapeutics operates in the Health & Wellness sector.
When did Monopar Therapeutics complete a stock split?▼
The last stock split for Monopar Therapeutics was on August 13, 2024 with a ratio of 1:5.
Where is Monopar Therapeutics headquartered?▼
Monopar Therapeutics is headquartered in WILMETTE, United States.